Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force

摘要: Objectives: We undertook a systematic literature review as background to the European League Against Rheumatism (EULAR) recommendations for conducting clinical trials in anti-neutrophil cytoplasm antibody associated vasculitis (AAV), and assess quality of evidence outcome measures AAV. Methods: Using Medline search, we categorised identified studies according diagnoses. Factors affecting remission, relapse, renal function overall survival were identified. Results: A total 44 papers reviewed from 502 by our search criteria. There was considerable inconsistency definitions end points. Remission rates varied 30% 93% Wegener granulomatosis (WG), 75% 89% microscopic polyangiitis (MPA) 81% 91% Churg–Strauss syndrome (CSS). The 5-year WG, MPA CSS 74–91%, 45–76% 60–97%. Relapse (variably defined) common first 2 years but frequency varied: 18% 60% 8% MPA, 35% CSS. rate WG 23% at 15 months 120 months. Methods used morbidity between studies. Ignoring variations stage disease, factors influencing included immunosuppressive therapy used, type organ involvement, presence ANCA, older age male gender. Conclusions: include pattern Methodological highlight need consensus on terminology future conduct